Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia

被引:4
|
作者
Malbora, Baris [1 ]
Avci, Zekai [1 ]
Ozbek, Namik [1 ]
机构
[1] Baskent Univ, Fac Med, Dept Pediat Hematol, TR-06490 Ankara, Turkey
关键词
Acute lymphoblastic leukemia; pegylated asparaginase; intravenous push; hypertriglyceridemia; treatment; LIPID ABNORMALITIES; PANCREATITIS; HYPERLIPEMIA;
D O I
10.3109/01480545.2011.640684
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Asparaginase treatment is associated with several adverse effects, including allergy, thromboembolic events, acute pancreatitis, altered liver function, and hyperglycemia. In addition, asparaginase can cause abnormalities in lipid metabolism, predominantly hypercholesterolemia and -triglyceridemia. Herein, we report on the case of a 5-year-old male presenting with acute severe hypertriglyceridemia caused by accidental pegylated asparaginase push during treatment of relapsed acute lymphoblastic leukemia. Hypertriglyceridemia did not occur after appropriate administrations of pegylated asparaginase before and after accidental drug infusions, so we speculate that the rate of pegylated asparaginase administration may have an effect on the serum triglyceride level.
引用
收藏
页码:463 / 466
页数:4
相关论文
共 50 条
  • [21] L-Asparaginase Treatment in Acute Lymphoblastic Leukemia
    Pieters, Rob
    Hunger, Stephen P.
    Boos, Joachim
    Rizzari, Carmelo
    Silverman, Lewis
    Baruchel, Andre
    Goekbuget, Nicola
    Schrappe, Martin
    Pui, Ching-Hon
    CANCER, 2011, 117 (02) : 238 - 249
  • [22] Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?
    Douer, Dan
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2008, 21 (04) : 647 - 658
  • [23] Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
    Paul, Shilpa
    Rausch, Caitlin R.
    Nasnas, Patrice E.
    Kantarjian, Hagop
    Jabbour, Elias J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (03) : 166 - 175
  • [24] Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia
    Kadia, Tapan M.
    Kantarjian, Hagop M.
    Thomas, Deborah A.
    O'Brien, Susan
    Estrov, Zeev
    Ravandi, Farhad
    Jabbour, Elias
    Pemmaraju, Naveen
    Daver, Naval
    Wang, Xuemei
    Jain, Preetesh
    Pierce, Sherry
    Brandt, Mark
    Garcia-Manero, Guillermo
    Cortes, Jorge
    Borthakur, Gautam
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (02) : 120 - 124
  • [25] ADMINISTRATION OF PEGYLATED ASPARAGINASE RESULTS IN HIGHER ASPARAGINASE ACTIVITY AT THE END OF INDUCTION AS COMPARED TO UNMODIFIED ASPARAGINASE IN ACUTE LYMPHOBLASTIC LEUKEMIA
    Bansal, D.
    Aggarwal, R.
    Salaria, M.
    Marwaha, R. K.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 215 - 215
  • [26] Treatment of relapsed acute lymphoblastic leukemia in childhood
    Lew, Glen
    CANCER INVESTIGATION, 2007, 25 : 61 - 62
  • [27] Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis
    Goepel, Wibke
    Schnetzke, Ulf
    Hochhaus, Andreas
    Scholl, Sebastian
    ANNALS OF HEMATOLOGY, 2016, 95 (11) : 1899 - 1901
  • [28] Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis
    Wibke Göpel
    Ulf Schnetzke
    Andreas Hochhaus
    Sebastian Scholl
    Annals of Hematology, 2016, 95 : 1899 - 1901
  • [29] Severe immunodeficiency associated with acute lymphoblastic leukemia and its treatment
    Raje, Nikita
    Snyder, Brenda L.
    Hill, David A.
    Streicher, Jenna L.
    Sullivan, Kate E.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 120 (05) : 537 - +
  • [30] ASPARAGINASE AND METHOTREXATE COMBINATION CHEMOTHERAPY IN RELAPSED ACUTE LYMPHOBLASTIC-LEUKEMIA IN ADULTS
    YAP, BS
    MCCREDIE, KB
    KEATING, MJ
    BODEY, GP
    FREIREICH, EJ
    CANCER TREATMENT REPORTS, 1981, 65 : 83 - 87